Notably, iP300w displayed superior efficacy against CIC::DUX4 sarcoma compared to A-485 [18], another P300/CBP inhibitor from the same spirocyclic chemical series found to be effective against certain hematological malignancies, androgen receptor-positive prostate cancer, and NUT midline carcinoma [19, 33]. Here, CREBBP is linked to nut midline carcinoma.